Unibest
← Back to patent-cliff list

Ridinilazole

Tier C — Watch / trade

Ridinilazole

Summit Pharmaceuticals International
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:DNA

Indications (approved):Clostridioides difficile infection

Regional status

US
Phase III
2019-01-28
EU
Phase III
2019-01-28
China
-
Japan
-

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 1 · Total yield /
RIDIN-00191-95-2RIDIN-002872-85-5Ridinilazole—API · Ridinilazole
CodeCAS No.Intermediate
RIDIN-00191-95-2[1,1'-biphenyl]-3,3',4,4'-tetraamine
RIDIN-002872-85-5isonicotinaldehyde
Ridinilazole--

Frequently asked questions

What are the approved indications of Ridinilazole?

Approved indications include: Clostridioides difficile infection.

When does the Ridinilazole patent expire?

No public expiry year is available for Ridinilazole yet; this page updates once verified.

How many synthesis routes are recorded for Ridinilazole?

1 synthesis routes are recorded; the shortest is 1 steps with / total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Ridinilazole intermediates?

All intermediates in Ridinilazole routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.

How do I get a quote for Ridinilazole intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-08